litlas
ログインアカウント作成

Vivek Subbiah

2009–2025 年に発表

250
論文数
24,864
被引用数
79
h 指数
232
i10 指数

被引用数

Vivek Subbiah の年別被引用数1996 年: 被引用 2 件1997 年: 被引用 2 件2000 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 1 件2006 年: 被引用 1 件2009 年: 被引用 4 件2010 年: 被引用 6 件2011 年: 被引用 4 件2012 年: 被引用 5 件2013 年: 被引用 2 件2015 年: 被引用 7 件2016 年: 被引用 66 件2017 年: 被引用 151 件2018 年: 被引用 153 件2019 年: 被引用 600 件2020 年: 被引用 1,106 件2021 年: 被引用 1,302 件2022 年: 被引用 1,394 件2023 年: 被引用 1,468 件2024 年: 被引用 2,346 件2025 年: 被引用 1,317 件2026 年: 被引用 24 件1998〜1999 年は被引用が無いため表示していません2001〜2002 年は被引用が無いため表示していません2005 年は被引用が無いため表示していません2007〜2008 年は被引用が無いため表示していません2014 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,973 件、この内訳の 26.3%中国: 引用元論文 1,285 件、この内訳の 11.3%イタリア: 引用元論文 773 件、この内訳の 6.8%イギリス: 引用元論文 562 件、この内訳の 5%フランス: 引用元論文 538 件、この内訳の 4.7%ドイツ: 引用元論文 531 件、この内訳の 4.7%スペイン: 引用元論文 454 件、この内訳の 4%日本: 引用元論文 348 件、この内訳の 3.1%カナダ: 引用元論文 336 件、この内訳の 3%オランダ: 引用元論文 292 件、この内訳の 2.6%スイス: 引用元論文 289 件、この内訳の 2.5%オーストラリア: 引用元論文 275 件、この内訳の 2.4%
0%26.3%その他 23.6%

機関

分野

  • Medicine66.3%
  • Biochemistry, Genetics and Molecular Biology26.6%
  • Immunology and Microbiology1.9%
  • Computer Science1%
  • Mathematics0.7%
  • Engineering0.6%
  • その他2.9%

トピック

  • Cancer Genomics and Diagnostics6.2%
  • Lung Cancer Treatments and Mutations5.9%
  • Cancer Immunotherapy and Biomarkers5.3%
  • Lung Cancer Research Studies3%
  • Thyroid Cancer Diagnosis and Treatment2.6%
  • Colorectal Cancer Treatments and Studies2.1%
  • その他74.9%

共著者

全論文

検索で開く
  1. The next generation of evidence-based medicine

    著者: Vivek Subbiah - Nature Medicine 2023 被引用: 528

  2. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

    著者: Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam, Hagop M. Kantarjian, Farhad Ravandi, Meghan Collins, Maria Emilia Di Francesco, Ecaterina E. Dumbrava, Siqing Fu, Sisi Gao, Jason Gay, Sonal Gera, Jing Han, David S. Hong, Elias Jabbour, Zhenlin Ju, Daniel D. Karp, Alessia Lodi, Jennifer R. Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A. Piha‐Paul, Jordi Rodón, Carolina Salguero, Koji Sasaki, Anand Kumar Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun A. Xu, Musa Yılmaz, Qi Zhang, Yuan Li, Christopher A. Bristow, Meenakshi B. Bhattacharjee, Stefano Tiziani, Timothy P. Heffernan, Christopher P. Vellano, Philip Jones, Cobi J. Heijnen, Annemieke Kavelaars, Joseph R. Marszalek, Marina Konopleva - Nature Medicine 2023 被引用: 377

  3. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

    著者: Vivek Subbiah, Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss, Masayuki Takeda, Yuichiro Ohe, Saad A. Khan, Kadoaki Ohashi, Victoria Soldatenkova, Sylwia Szymczak, Loretta Sullivan, Jennifer Wright, Alexander Drilon - The Lancet Oncology 2022 被引用: 420

  4. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    著者: Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 被引用: 836

  5. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    著者: David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean‐Yves Blay, Jürgen Wolf, Noopur Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoîne Italiano, Ralf‐Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schüler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzén, Maria Luisa Veronese, Josep Tabernero, José Baselga - New England Journal of Medicine 2015 被引用: 1,734

  6. Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

    著者: Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas - New England Journal of Medicine 2020 被引用: 773

  7. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

    著者: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J.A. de Jonge, Jean‐Yves Blay, Antoîne Italiano, Kan Yonemori, Daniel C. Cho, Filip De Vos, Philippe Moreau, Elena Élez, Jan H.M. Schellens, Christoph Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung‐Jue Bang - Nature Medicine 2023 被引用: 298

  8. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    著者: Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan, Elena Garralda, Luis Paz‐Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen V. Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah - The Lancet Oncology 2021 被引用: 443

  9. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    著者: Giannis Mountzios, Jordi Remón, Lizza Hendriks, Rosario García‐Campelo, Christian Rolfo, Paul Van Schil, Patrick M. Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean‐Charles Soria, Solange Peters - Nature Reviews Clinical Oncology 2023 被引用: 182

  10. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    著者: Vivek Subbiah, Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg - The Lancet Oncology 2020 被引用: 518

  11. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    著者: José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares - The Lancet Oncology 2020 被引用: 462

  12. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

    著者: Patrick Y Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos, Nikolas von Bubnoff, Myra E van Linde, Albert Lai, Gerald W Prager, Mario Campone, Angelica Fasolo, Jose A Lopez-Martin, Tae Min Kim, Warren P Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah - The Lancet Oncology 2021 被引用: 353

  13. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

    著者: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean Charles Soria, Patrick Y. Wen, Christoph Zielinski, Maria E. Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, Fatima Rangwala, Bhumsuk Keam - Journal of Clinical Oncology 2017 被引用: 885

  14. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

    著者: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria, Patrick Y. Wen, C. C. Zielinski, Maria E. Cabanillas, Aislyn Boran, Palanichamy Ilankumaran, P. Burgess, T. Romero Salas, Bhumsuk Keam - Annals of Oncology 2022 被引用: 346

  15. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

    著者: Matteo Palmeri, Janice M. Mehnert, Ann W. Silk, Salma K. Jabbour, Shridar Ganesan, Pallvi Popli, Gregory Riedlinger, Ryan D. Stephenson, Alexandre Buckley de Meritens, Aliza Leiser, Tina Mayer, Nancy Chan, Kristen Spencer, Eugenia Girda, Jyoti Malhotra, Timothy A. Chan, Vivek Subbiah, Roman Groisberg - ESMO Open 2021 被引用: 353

  16. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    著者: Vivek Subbiah, Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P. Kalemkerian, Daniel W. Bowles, ­Mahesh Seetharam, Jianhua Chang, Hui Zhang, Jennifer Green, Alena Zalutskaya, Martin Schüler, Yun Fan, Giuseppe Curigliano - Nature Medicine 2022 被引用: 239

  17. Clinical Development of BRAF plus MEK Inhibitor Combinations

    著者: Vivek Subbiah, Christina S. Baik, John M. Kirkwood - Trends in cancer 2020 被引用: 352

  18. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

    著者: Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin Solomon, Daniel S.W. Tan, Guzmán Alonso, Jürgen Wolf, Keunchil Park, Kōichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott Barker, Tarun Puri, Aimee Bence Lin, Herbert H. Loong, Benjamin Besse - Journal of Clinical Oncology 2022 被引用: 205

  19. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

    著者: Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry Touré, Songping Zhao, Roberto Valverde, Patrick J. O’Hearn, Demetri T. Moustakas, Heike Schönherr, Nastaran Gerami-Moayed, Alexander M. Taylor, Brandi M. Hudson, Damian J. Houde, Debjani Pal, Lindsey Foster, Hakan Günaydin, Pelin Ayaz, Dina A. Sharon, Lipika Goyal, Alison M. Schram, Suneel Kamath, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Kai Yu Jen, Fabien Ricard, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, Jessica B. Casaletto - Cancer Discovery 2023 被引用: 119

  20. Drugging KRAS: current perspectives and state-of-art review

    著者: Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah, Alfredo Addeo - Journal of Hematology & Oncology 2022 被引用: 146

  21. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    著者: Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano, Marcia S. Brose, Viola W. Zhu, Sophie Leboulleux, Daniel W. Bowles, Christina S. Baik, Douglas Adkins, Bhumsuk Keam, Ignacio Matos, Elena Garralda, Justin F. Gainor, Gilberto Lopes, Chia‐Chi Lin, Yann Godbert, Debashis Sarker, Stephen G. Miller, Corinne Clifford, Hui Zhang, Christopher D. Turner, Matthew H. Taylor - The Lancet Diabetes & Endocrinology 2021 被引用: 353

  22. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

    著者: Frank Griesinger, Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan, Daniel Lee, D Misch, Elena Garralda, D.-W. Kim, Anthonie J. van der Wekken, Justin F. Gainor, Luis Paz‐Ares, Stephen V. Liu, Gregory P. Kalemkerian, Yariv Houvras, Daniel W. Bowles, Aaron S. Mansfield, W. Marston Linehan, Vlatka Smoljanović, Ahmadur Rahman, Shengchun Kong, Alena Zalutskaya, Melinda Louie-Gao, Andy Boral, Julien Mazières - Annals of Oncology 2022 被引用: 178

  23. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

    著者: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock - Annals of Oncology 2020 被引用: 250

  24. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

    著者: Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo, Alfredo Addeo - Nature Reviews Clinical Oncology 2021 被引用: 198